Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer

Abstract excerpt

BACKGROUND: The cutoff of <1% positive cells to define estrogen receptor (ER) negativity by immunohistochemistry (IHC) in breast cancer (BC) is debated. We explored the tumor immune microenvironment and gene-expression profile of patients with early-stage HER2-negative ER-low (ER 1%-9%) BC, comparing them to ER-negative (ER <1%) and ER-intermediate (ER 10%-50%) tumors. METHODS: Among 921 patients with early-stage...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Breast Cancer Treatment Studies
• Share to Cancer Immunotherapy and Biomarkers
• Share to Estrogen and related hormone effects